Materiały źródłowe

• #1 Precocious puberty – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/precocious-puberty/diagnosis-treatment/drc-20351817

  The primary goal of treatment is for children to grow to adult height. […] Treatment for precocious puberty depends on the cause. However, when no cause can be found, treatment may not be needed, depending on the child’s age and how fast puberty is moving. Watching the child for several months might be an option. […] This usually involves medicine called GnRH analogue therapy, which delays further development. It may be a monthly shot with medicine such as leuprolide acetate (Lupron Depot), or triptorelin (Trelstar, Triptodur Kit). Or some newer formulations can be given at longer intervals. […] Children keep getting this medicine until they reach the usual age of puberty. After the treatment stops, puberty starts again. […] Another treatment option for central precocious puberty is a histrelin implant, which lasts up to a year. This treatment doesn’t involve monthly shots. But it does involve minor surgery to put the implant under the skin of the upper arm. After a year, the implant is removed. If needed, a new implant takes its place. […] If another medical condition is causing precocious puberty, stopping puberty means treating that condition. For example, if a tumor makes hormones that cause precocious puberty, puberty usually stops after taking out the tumor.

• #2 Precocious Puberty – Early Puberty: Symptoms & Causes

  https://my.clevelandclinic.org/health/diseases/21064-precocious-early-puberty

  Precocious puberty treatment depends on the type. […] Turning off the pituitary glands production of LH and FSH is the main goal of central precocious puberty treatment. Turning off production will slow down the signs of puberty and delay menstruation. Treatment typically includes a GnRH agonist (puberty blocker), a synthetic (human-made) hormone that works by halting the production of reproductive or growth hormones. Your childs provider will give your child an injection of the medication at regular intervals until its safe for puberty to begin. […] Eliminating the source of reproductive hormones is the treatment for peripheral precocious puberty. Some children need surgery to remove a tumor or another mass thats causing the symptoms of early puberty. Others may need medication like a steroid called a glucocorticoid. Removing an outside source of reproductive hormones, like estrogen creams, may be enough to stop early puberty.

• #3 Precocious Puberty – Early Puberty: Symptoms & Causes

  https://my.clevelandclinic.org/health/diseases/21064-precocious-early-puberty

  Precocious puberty treatment depends on the type. […] Turning off the pituitary glands production of LH and FSH is the main goal of central precocious puberty treatment. Turning off production will slow down the signs of puberty and delay menstruation. Treatment typically includes a GnRH agonist (puberty blocker), a synthetic (human-made) hormone that works by halting the production of reproductive or growth hormones. Your childs provider will give your child an injection of the medication at regular intervals until its safe for puberty to begin. […] Eliminating the source of reproductive hormones is the treatment for peripheral precocious puberty. Some children need surgery to remove a tumor or another mass thats causing the symptoms of early puberty. Others may need medication like a steroid called a glucocorticoid. Removing an outside source of reproductive hormones, like estrogen creams, may be enough to stop early puberty.

• #4 Precocious Puberty | Riley Children’s Health

  https://www.rileychildrens.org/health-info/precocious-puberty

  Precocious puberty in girls is when the following happens before the age of 8: […] Precocious puberty in boys is when the following happens before the age of 9: […] There are two types of precocious puberty: […] Treatment of precocious puberty depends on if your child is diagnosed with central precocious puberty or peripheral precocious puberty: […] Central precocious puberty. Some forms of CPP do not require any treatment, particularly if it is slowly progressing and your child is close to the normal age. If treatment for CPP is required, the goal is to temporarily stop production of luteinizing hormone (LH) and follicle stimulating hormone (FSH) by the pituitary gland. A gonadotropin-releasing hormone (GnRH) agonist is used to treat CPP and suppress pituitary gonadal function. […] Peripheral precocious puberty. Treatment of PPP varies depending on the cause. If the cause is a tumor that is producing estrogen or testosterone, treatment may include removal of the tumor. The doctor may also prescribe medicines that suppress or stop estrogen or testosterone production.

• #5 Treatment of Central Precocious Puberty

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6486823/

  Long-acting analogs of GnRH (GnRHas) have been the gold-standard treatment of central precocious puberty (CPP) worldwide and have an enviable track record of safety and efficacy. […] Safe and effective treatment of CPP in the form of long-acting GnRH analogs (GnRHas) has been available for many years. […] Historically, the most commonly used preparation in the United States for the treatment of CPP was monthly IM depot leuprolide. […] However, during the past decade or so, there has been a substantial increase in the number of extended-release formulations of GnRHas, resulting in a broad array of therapeutic options for patients and providers. […] Although these longer-acting formulations are expected to improve compliance, the cost of GnRHas developed for use in children has remained extremely high.

• #6 Precocious Puberty Medication: Gonadotropin-Releasing Hormone Agonists, Progestin

  https://emedicine.medscape.com/article/924002-medication

  Continuous administration of GnRH agonists suppresses pituitary production of gonadotropins because they provide constant stimulus, whereas the pituitary responds only to pulsatile GnRH stimulation. […] GnRH agonists are safe and effective, resulting in decreased levels of LH, FSH, and sex steroids within 4 weeks after initiation of treatment. […] Initially, the 1-month formulation of leuprolide, called Lupron Depot, was the mainstay of therapy. […] In 2011, 3-month formulations of Lupron Depot were approved for children with precocious puberty. […] A review of the landscape of GnRH therapies available in the United States discusses the advantages of the different injectable preparations as well as the histrelin implant, which lasts at least a year (and which some studies indicate may last 2 or more years).

• #7 Precocious Puberty (for Parents) | Nemours KidsHealth

  https://kidshealth.org/en/parents/precocious.html

  If your child has precocious puberty, the doctor may refer you to a pediatric endocrinologist (a doctor who treats growth and hormone disorders in children) for treatment. […] The treatment goals are to: stop or even reverse sexual development, stop the rapid growth and bone maturation that can lead to adult short stature or an early start to periods. […] Depending upon the cause, there are two possible approaches to treatment: treating the underlying cause or disease, lowering the high levels of sex hormones with medicine to stop sexual development. […] Sometimes, treatment of a related health problem can stop the precocious puberty. But in most cases, there’s no other disease, so treatment usually involves hormone therapy to stop sexual development. […] The currently approved hormone treatment is with drugs called LHRH analogs. These synthetic (man-made) hormones block the body’s production of the sex hormones that cause early puberty. Positive results usually are seen within a year of starting treatment. LHRH analogs are generally safe and usually cause no side effects in kids. […] In girls, breast size may decrease. In boys, the penis and testicles may shrink back to the size expected for their age. Growth in height will also slow down to a rate expected for kids before puberty. A child’s behavior usually becomes more age-appropriate too.

• #8 Treatment of Central Precocious Puberty

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6486823/

  Long-acting analogs of GnRH (GnRHas) have been the gold-standard treatment of central precocious puberty (CPP) worldwide and have an enviable track record of safety and efficacy. […] Safe and effective treatment of CPP in the form of long-acting GnRH analogs (GnRHas) has been available for many years. […] Historically, the most commonly used preparation in the United States for the treatment of CPP was monthly IM depot leuprolide. […] However, during the past decade or so, there has been a substantial increase in the number of extended-release formulations of GnRHas, resulting in a broad array of therapeutic options for patients and providers. […] Although these longer-acting formulations are expected to improve compliance, the cost of GnRHas developed for use in children has remained extremely high.

• #9 Precocious Puberty Medication: Gonadotropin-Releasing Hormone Agonists, Progestin

  https://emedicine.medscape.com/article/924002-medication

  Triptorelin is indicated for central precocious puberty (CPP) in pediatric patients aged 2 years or older; works by the same mechanism as leuprolide. […] Histrelin is a potent inhibitor of gonadotropin secretion when administered long-term. […] The implant provides continuous SC release of histrelin at a nominal rate of 50-65 mcg/d over 12 months and is safe and effective for CPP. […] The main disadvantage is the need to have visits with a surgeon to place and remove the implant, usually with light sedation, which increases the already high cost of about $40,000 per implant. […] Available in a monthly depot formulation in 7.5-, 11.25-, and 15-mg doses and for the every 3-month formulation, in 11.25- and 30-mg doses. […] Individualize duration of therapy according to age and maturity of child and predicted adult height; in most cases, continuing treatment after age 10 years is unnecessary.

• #10 Understanding Central Precocious Puberty | LUPRON DEPOT-PED® (leuprolide acetate for depot suspension)

  https://www.lupronped.com/understanding-central-precocious-puberty

  Puberty that starts too soon is called precocious puberty. The most common type is Central Precocious Puberty (CPP). Children with CPP that is left untreated will keep going through puberty and that can have lasting complications beyond childhood. […] If you suspect your child has CPP, don’t waitact now and notify your child’s pediatrician. They can refer you to a pediatric endocrinologist who can appropriately diagnose your child and determine the right treatment plan for them. […] If youre worried that your child may have CPP, talk to their pediatrician and ask for a referral to a pediatric endocrinologist. With an appropriate treatment plan, you can help control your childs CPP. […] LUPRON DEPOT-PED 7.5 mg, 11.25 mg, and 15 mg for 1-month, 11.25 mg and 30 mg for 3-month, and 45 mg for 6-month administration are prescribed for the treatment of children with central precocious puberty (CPP).

• #11 Treatment of Central Precocious Puberty

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6486823/

  This review discusses each of the extended-release GnRHa formulations currently in the therapeutic armamentarium, describes areas of uncertainty in clinical management, and highlights unanswered questions and future directions. […] A 6-monthly form of depot triptorelin was approved in 2017 by the US Food and Drug Administration for use in CPP. […] A subcutaneous implant containing 50 mg of the potent GnRHa histrelin has been available for the treatment of CPP since 2007. […] The implant is typically inserted in the upper inner arm using local anesthesia in most cases. […] Although marketed for annual use, the recognition that a single implant lasts at least 2 years has the potential to decrease costs and numbers of surgical procedures in children treated with this modality. […] GnRHas have an admirable safety profile.

• #12 FDA Approves Precocious Puberty Treatment | Consultant360

  https://www.consultant360.com/exclusives/fda-approves-precocious-puberty-treatment

  The FDA has approved Triptodur, Triptorelin 6-month Formulation, for the treatment of pediatric patients 2 years and older with central precocious puberty (CPP). […] The gonadotropin-releasing hormone (GnRH) agonist is administered via intramuscular injection and is the first GnRH agonist to offer once-every-6-months dosing approved for the treatment of CPP in the US. […] The effectiveness of Triptodur was established in a phase III clinical trial in which 93% of participants given the drug experienced a return to pre-pubertal luteinizing hormone levels and pre-pubertal luteinizing hormone suppression maintained at 12 months in 98% of participants. […] The most common adverse events experienced by patients taking Triptodur were injection site reactions and menstrual bleeding.

• #13 Treatment of Central Precocious Puberty

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6486823/

  This review discusses each of the extended-release GnRHa formulations currently in the therapeutic armamentarium, describes areas of uncertainty in clinical management, and highlights unanswered questions and future directions. […] A 6-monthly form of depot triptorelin was approved in 2017 by the US Food and Drug Administration for use in CPP. […] A subcutaneous implant containing 50 mg of the potent GnRHa histrelin has been available for the treatment of CPP since 2007. […] The implant is typically inserted in the upper inner arm using local anesthesia in most cases. […] Although marketed for annual use, the recognition that a single implant lasts at least 2 years has the potential to decrease costs and numbers of surgical procedures in children treated with this modality. […] GnRHas have an admirable safety profile.

• #14 Precocious puberty – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/precocious-puberty/diagnosis-treatment/drc-20351817

  The primary goal of treatment is for children to grow to adult height. […] Treatment for precocious puberty depends on the cause. However, when no cause can be found, treatment may not be needed, depending on the child’s age and how fast puberty is moving. Watching the child for several months might be an option. […] This usually involves medicine called GnRH analogue therapy, which delays further development. It may be a monthly shot with medicine such as leuprolide acetate (Lupron Depot), or triptorelin (Trelstar, Triptodur Kit). Or some newer formulations can be given at longer intervals. […] Children keep getting this medicine until they reach the usual age of puberty. After the treatment stops, puberty starts again. […] Another treatment option for central precocious puberty is a histrelin implant, which lasts up to a year. This treatment doesn’t involve monthly shots. But it does involve minor surgery to put the implant under the skin of the upper arm. After a year, the implant is removed. If needed, a new implant takes its place. […] If another medical condition is causing precocious puberty, stopping puberty means treating that condition. For example, if a tumor makes hormones that cause precocious puberty, puberty usually stops after taking out the tumor.

• #15 Treatment of Central Precocious Puberty

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6486823/

  Long-acting analogs of GnRH (GnRHas) have been the gold-standard treatment of central precocious puberty (CPP) worldwide and have an enviable track record of safety and efficacy. […] Safe and effective treatment of CPP in the form of long-acting GnRH analogs (GnRHas) has been available for many years. […] Historically, the most commonly used preparation in the United States for the treatment of CPP was monthly IM depot leuprolide. […] However, during the past decade or so, there has been a substantial increase in the number of extended-release formulations of GnRHas, resulting in a broad array of therapeutic options for patients and providers. […] Although these longer-acting formulations are expected to improve compliance, the cost of GnRHas developed for use in children has remained extremely high.

• #16 Precocious Puberty Medication: Gonadotropin-Releasing Hormone Agonists, Progestin

  https://emedicine.medscape.com/article/924002-medication

  Triptorelin is indicated for central precocious puberty (CPP) in pediatric patients aged 2 years or older; works by the same mechanism as leuprolide. […] Histrelin is a potent inhibitor of gonadotropin secretion when administered long-term. […] The implant provides continuous SC release of histrelin at a nominal rate of 50-65 mcg/d over 12 months and is safe and effective for CPP. […] The main disadvantage is the need to have visits with a surgeon to place and remove the implant, usually with light sedation, which increases the already high cost of about $40,000 per implant. […] Available in a monthly depot formulation in 7.5-, 11.25-, and 15-mg doses and for the every 3-month formulation, in 11.25- and 30-mg doses. […] Individualize duration of therapy according to age and maturity of child and predicted adult height; in most cases, continuing treatment after age 10 years is unnecessary.

• #17 Precocious Puberty – Early Puberty: Symptoms & Causes

  https://my.clevelandclinic.org/health/diseases/21064-precocious-early-puberty

  Precocious puberty treatment depends on the type. […] Turning off the pituitary glands production of LH and FSH is the main goal of central precocious puberty treatment. Turning off production will slow down the signs of puberty and delay menstruation. Treatment typically includes a GnRH agonist (puberty blocker), a synthetic (human-made) hormone that works by halting the production of reproductive or growth hormones. Your childs provider will give your child an injection of the medication at regular intervals until its safe for puberty to begin. […] Eliminating the source of reproductive hormones is the treatment for peripheral precocious puberty. Some children need surgery to remove a tumor or another mass thats causing the symptoms of early puberty. Others may need medication like a steroid called a glucocorticoid. Removing an outside source of reproductive hormones, like estrogen creams, may be enough to stop early puberty.

• #18 Precocious Puberty | Riley Children’s Health

  https://www.rileychildrens.org/health-info/precocious-puberty

  Precocious puberty in girls is when the following happens before the age of 8: […] Precocious puberty in boys is when the following happens before the age of 9: […] There are two types of precocious puberty: […] Treatment of precocious puberty depends on if your child is diagnosed with central precocious puberty or peripheral precocious puberty: […] Central precocious puberty. Some forms of CPP do not require any treatment, particularly if it is slowly progressing and your child is close to the normal age. If treatment for CPP is required, the goal is to temporarily stop production of luteinizing hormone (LH) and follicle stimulating hormone (FSH) by the pituitary gland. A gonadotropin-releasing hormone (GnRH) agonist is used to treat CPP and suppress pituitary gonadal function. […] Peripheral precocious puberty. Treatment of PPP varies depending on the cause. If the cause is a tumor that is producing estrogen or testosterone, treatment may include removal of the tumor. The doctor may also prescribe medicines that suppress or stop estrogen or testosterone production.

• #19 Precocious Puberty – Pediatrics – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/pediatrics/endocrine-disorders-in-children/precocious-puberty

  In girls with McCune-Albright syndrome, aromatase inhibitors, such as letrozole and anastrozole, have been used with varying success to reduce estradiol […] If GnRH-independent precocious puberty in boys is due to familial male gonadotropin-independent precocity or McCune-Albright syndrome, androgen antagonists (eg, spironolactone) ameliorate the effects of excess androgen […] If GnRH-independent precocious puberty is due to a hormone-producing tumor (eg, granulosa-theca cell tumors in girls, testicular tumors in boys), the tumor should be excised. However, girls require extended follow-up to check for recurrence in the contralateral ovary.

• #20 Precocious Puberty (Causes, Symptoms, and Treatment)

  https://patient.info/doctor/precocious-puberty-pro

  Precocious puberty treatment and management […] For cases of CPP with no underlying brain pathology and no psychosocial complications, treatment for the pubertal changes alone may not be required. Puberty can be arrested and growth hormone given if the height prognosis is poor. Examples of treatment include: […] Medical treatments include: GnRH agonists – used in CPP, as well as for other aetiologies, including MAS and testotoxicosis. These come in a number of depot preparations. They work by overstimulating the pituitary gland, causing desensitisation and thereby less release of LH and FSH. They are continued until the time for normal puberty arrives. If started early they can help the individual achieve predicted adult height. […] Glucocorticoids – used for CAH. […] Testolactone – an aromatase inhibitor (therefore inhibits steroid biosynthesis). It is used most commonly for MAS but also in testotoxicosis. Other aromatase inhibitors such as letrozole and anastrozole have also been used in small case studies for MAS.

• #21 Precocious Puberty | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/27608

  Central precocious puberty (CPP) represents true pubertal development due to the earlier maturation and activation of the HPG axis. […] The decision to treat depends on the age of the child and the progression of puberty. If the child has rapidly progressing symptoms or if bone age is significantly advanced, consider treatment. The main goals of treatment are to preserve the adult height and to alleviate the associated psychosocial stress. GnRH agonists are the standard of care. […] Treatment is directed towards eliminating the source of sex steroids. Surgery is indicated in gonadal and adrenal tumors. If exogenous sources of sex steroids are identified, they should be eliminated. Classic congenital CAH is treated with glucocorticoids. In McCune-Albright syndrome, some benefit occurs with blocking the estrogen synthesis using aromatase inhibitors (anastrozole, letrozole) and selective estrogen selective receptor modulator (tamoxifen). […] While on treatment, periodic monitoring of pubertal progression, growth velocity, and skeletal maturation are necessary.

• #22 Precocious Puberty – Pediatrics – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/pediatrics/endocrine-disorders-in-children/precocious-puberty

  In girls with McCune-Albright syndrome, aromatase inhibitors, such as letrozole and anastrozole, have been used with varying success to reduce estradiol […] If GnRH-independent precocious puberty in boys is due to familial male gonadotropin-independent precocity or McCune-Albright syndrome, androgen antagonists (eg, spironolactone) ameliorate the effects of excess androgen […] If GnRH-independent precocious puberty is due to a hormone-producing tumor (eg, granulosa-theca cell tumors in girls, testicular tumors in boys), the tumor should be excised. However, girls require extended follow-up to check for recurrence in the contralateral ovary.

• #23 Precocious Puberty (Causes, Symptoms, and Treatment)

  https://patient.info/doctor/precocious-puberty-pro

  Precocious puberty treatment and management […] For cases of CPP with no underlying brain pathology and no psychosocial complications, treatment for the pubertal changes alone may not be required. Puberty can be arrested and growth hormone given if the height prognosis is poor. Examples of treatment include: […] Medical treatments include: GnRH agonists – used in CPP, as well as for other aetiologies, including MAS and testotoxicosis. These come in a number of depot preparations. They work by overstimulating the pituitary gland, causing desensitisation and thereby less release of LH and FSH. They are continued until the time for normal puberty arrives. If started early they can help the individual achieve predicted adult height. […] Glucocorticoids – used for CAH. […] Testolactone – an aromatase inhibitor (therefore inhibits steroid biosynthesis). It is used most commonly for MAS but also in testotoxicosis. Other aromatase inhibitors such as letrozole and anastrozole have also been used in small case studies for MAS.

• #24 Precocious Puberty | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/27608

  Central precocious puberty (CPP) represents true pubertal development due to the earlier maturation and activation of the HPG axis. […] The decision to treat depends on the age of the child and the progression of puberty. If the child has rapidly progressing symptoms or if bone age is significantly advanced, consider treatment. The main goals of treatment are to preserve the adult height and to alleviate the associated psychosocial stress. GnRH agonists are the standard of care. […] Treatment is directed towards eliminating the source of sex steroids. Surgery is indicated in gonadal and adrenal tumors. If exogenous sources of sex steroids are identified, they should be eliminated. Classic congenital CAH is treated with glucocorticoids. In McCune-Albright syndrome, some benefit occurs with blocking the estrogen synthesis using aromatase inhibitors (anastrozole, letrozole) and selective estrogen selective receptor modulator (tamoxifen). […] While on treatment, periodic monitoring of pubertal progression, growth velocity, and skeletal maturation are necessary.

• #25 Precocious Puberty (Causes, Symptoms, and Treatment)

  https://patient.info/doctor/precocious-puberty-pro

  Tamoxifen – has been used in MAS. […] Ketoconazole – may be used (for example, in testotoxicosis) to inhibit steroid biosynthesis. […] Cyproterone acetate – may be used for anti-androgen action. Flutamide is also used to counter androgen excess. […] Medroxyprogesterone (a progesterone analogue) – has also been used.

• #26 Precocious Puberty (Causes, Symptoms, and Treatment)

  https://patient.info/doctor/precocious-puberty-pro

  Tamoxifen – has been used in MAS. […] Ketoconazole – may be used (for example, in testotoxicosis) to inhibit steroid biosynthesis. […] Cyproterone acetate – may be used for anti-androgen action. Flutamide is also used to counter androgen excess. […] Medroxyprogesterone (a progesterone analogue) – has also been used.

• #27 Precocious Puberty – Early Puberty: Symptoms & Causes

  https://my.clevelandclinic.org/health/diseases/21064-precocious-early-puberty

  Precocious puberty treatment depends on the type. […] Turning off the pituitary glands production of LH and FSH is the main goal of central precocious puberty treatment. Turning off production will slow down the signs of puberty and delay menstruation. Treatment typically includes a GnRH agonist (puberty blocker), a synthetic (human-made) hormone that works by halting the production of reproductive or growth hormones. Your childs provider will give your child an injection of the medication at regular intervals until its safe for puberty to begin. […] Eliminating the source of reproductive hormones is the treatment for peripheral precocious puberty. Some children need surgery to remove a tumor or another mass thats causing the symptoms of early puberty. Others may need medication like a steroid called a glucocorticoid. Removing an outside source of reproductive hormones, like estrogen creams, may be enough to stop early puberty.

• #28 Precocious Puberty Treatment & Management: Approach Considerations, Surgical Care, Medical Care

  https://emedicine.medscape.com/article/924002-treatment

  For patients with precocious puberty treated with GnRH agonists: Follow up every 4-6 months to ensure that progression of puberty has been arrested. Favorable signs include normalization of accelerated growth, reduction (or at least no increase) in breast size, and suppression of gonadotropin levels after a challenge of GnRH. The ideal testing frequency has not been established, although one approach is to obtain a GnRH test about 4 months after starting the drug to confirm suppression and then conduct such testing no more often than yearly, as long as clinical indicators suggest that the drug is working as intended; some clinicians advocate dispensing with formal GnRH testing as long as growth has slowed and breasts have decreased in size; in boys, a decrease in the size of the testes and a fall in the serum testosterone level to less than 20 ng/dL are good indications of efficacy. Monitor bone age yearly to confirm that the rapid advancement seen in the untreated state has slowed, typically to a half year of bone age per year or less.

• #29 2022 Clinical practice guidelines for central precocious puberty of Korean children and adolescents

  https://e-apem.org/journal/view.php?number=994

  Immediate evaluation and treatment are recommended when SCFE, pseudotumor cerebri, or anaphylaxis occurs during GnRH agonist treatment. […] It is recommended to evaluate the effects of GnRH agonist treatment every 3 to 6 months. […] After GnRH agonist treatment, regular follow-up is recommended until the FAH is reached and the recovery of gonadal function is confirmed. […] GnRH agonist treatment does not affect reproductive function nor increase the risk of PCOS in patients with CPP. […] GnRH agonist treatment does not affect metabolic disease, bone health, or mental health in patients with CPP. […] The second edition of 2022 CPGs for the CPP of Korean children and adolescents has been revised and supplements the previous edition based on the latest domestic and international research.

• #30 Precocious Puberty Treatment & Management: Approach Considerations, Surgical Care, Medical Care

  https://emedicine.medscape.com/article/924002-treatment

  For patients with precocious puberty treated with GnRH agonists: Follow up every 4-6 months to ensure that progression of puberty has been arrested. Favorable signs include normalization of accelerated growth, reduction (or at least no increase) in breast size, and suppression of gonadotropin levels after a challenge of GnRH. The ideal testing frequency has not been established, although one approach is to obtain a GnRH test about 4 months after starting the drug to confirm suppression and then conduct such testing no more often than yearly, as long as clinical indicators suggest that the drug is working as intended; some clinicians advocate dispensing with formal GnRH testing as long as growth has slowed and breasts have decreased in size; in boys, a decrease in the size of the testes and a fall in the serum testosterone level to less than 20 ng/dL are good indications of efficacy. Monitor bone age yearly to confirm that the rapid advancement seen in the untreated state has slowed, typically to a half year of bone age per year or less.

• #31 Precocious Puberty Treatment & Management: Approach Considerations, Surgical Care, Medical Care

  https://emedicine.medscape.com/article/924002-treatment

  For patients with precocious puberty treated with GnRH agonists: Follow up every 4-6 months to ensure that progression of puberty has been arrested. Favorable signs include normalization of accelerated growth, reduction (or at least no increase) in breast size, and suppression of gonadotropin levels after a challenge of GnRH. The ideal testing frequency has not been established, although one approach is to obtain a GnRH test about 4 months after starting the drug to confirm suppression and then conduct such testing no more often than yearly, as long as clinical indicators suggest that the drug is working as intended; some clinicians advocate dispensing with formal GnRH testing as long as growth has slowed and breasts have decreased in size; in boys, a decrease in the size of the testes and a fall in the serum testosterone level to less than 20 ng/dL are good indications of efficacy. Monitor bone age yearly to confirm that the rapid advancement seen in the untreated state has slowed, typically to a half year of bone age per year or less.

• #32 Precocious Puberty Treatment & Management: Approach Considerations, Surgical Care, Medical Care

  https://emedicine.medscape.com/article/924002-treatment

  For patients with precocious puberty treated with GnRH agonists: Follow up every 4-6 months to ensure that progression of puberty has been arrested. Favorable signs include normalization of accelerated growth, reduction (or at least no increase) in breast size, and suppression of gonadotropin levels after a challenge of GnRH. The ideal testing frequency has not been established, although one approach is to obtain a GnRH test about 4 months after starting the drug to confirm suppression and then conduct such testing no more often than yearly, as long as clinical indicators suggest that the drug is working as intended; some clinicians advocate dispensing with formal GnRH testing as long as growth has slowed and breasts have decreased in size; in boys, a decrease in the size of the testes and a fall in the serum testosterone level to less than 20 ng/dL are good indications of efficacy. Monitor bone age yearly to confirm that the rapid advancement seen in the untreated state has slowed, typically to a half year of bone age per year or less.

• #33 Management of precocious puberty

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3891356/

  The objectives of treatment for children with central precocious puberty (CPP) are to avoid psychosocial problems caused by early pubertal development and to normalize adult height (AH). A long-acting GnRH analog is the treatment of choice for CPP. GnRH analog administration effectively arrests further development of secondary sex characteristics, slows bone age (BA) maturation, increases pubertal height gain, and is believed to eventually improve AH prognosis. However, the improvement of AH is not well established. It is reported that GnRH analog is effective to improve adult height only in early onset (girls 6 years) CPP. […] The decision to stop therapy should be individualized and based on various factors such as growth velocity, bone age, chronological age, predicted adult height, emotional maturity, and patients wish. […] After treatment discontinuation, long-term follow up is recommended for adult height, reproductive function and bone mineral density.

• #34 Clinical Management and Therapy of Precocious Puberty in the Sapienza University Pediatrics Hospital of Rome, Italy

  https://www.mdpi.com/2227-9067/10/10/1672

  The gold standard in the CPP treatment is represented by GnRH analogs (GnRHa). […] Currently, there are no firm data establishing criteria for discontinuation of GnRHa therapy. […] However, numerous pieces of evidences suggest that the therapy should be suspended at the mean physiological age in which puberty occurs (between 10.5 and 11.5 years in females and between 12 and 13 years in males), or when a bone age of around 12 years in girls and 13 years in boys is reached or in cases of a marked reduction of growth velocity during therapy. […] When CPP is caused by a CNS lesion, therapy is also directed toward the underlying pathology when possible. Treatment of PPP is instead aimed at blocking the secretion and/or response to the sex steroids, since PPP does not respond to GnRHa therapy, and therefore varies according to the underlying condition.

• #35 Treatment of Central Precocious Puberty

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6486823/

  The most commonly reported adverse events are injection-site reactions which are typically mild and self-limited. […] The main goal of treatment in children with CPP is the preservation of height potential. […] A period of observation of 6 months has been recommended unless puberty is quite advanced (Tanner stage 3 breast development in girls) at initial presentation. […] The challenge lies in identifying which patients will ultimately belong in this category as compared with those who will lose a substantial degree of height potential without treatment. […] There are essentially no studies in which age at treatment cessation has been standardized. […] However, cumulative evidence suggests that optimal height gains are realized when treatment is stopped at a bone age of 12 years in girls and 13 years in boys.

• #36 Clinical Management and Therapy of Precocious Puberty in the Sapienza University Pediatrics Hospital of Rome, Italy

  https://www.mdpi.com/2227-9067/10/10/1672

  The gold standard in the CPP treatment is represented by GnRH analogs (GnRHa). […] Currently, there are no firm data establishing criteria for discontinuation of GnRHa therapy. […] However, numerous pieces of evidences suggest that the therapy should be suspended at the mean physiological age in which puberty occurs (between 10.5 and 11.5 years in females and between 12 and 13 years in males), or when a bone age of around 12 years in girls and 13 years in boys is reached or in cases of a marked reduction of growth velocity during therapy. […] When CPP is caused by a CNS lesion, therapy is also directed toward the underlying pathology when possible. Treatment of PPP is instead aimed at blocking the secretion and/or response to the sex steroids, since PPP does not respond to GnRHa therapy, and therefore varies according to the underlying condition.

• #37 Central Precocious Puberty: What to Expect During Treatment

  https://www.webmd.com/parenting/central-precocious-puberty-treatment

  In most cases, doctors dont know what causes central precocious puberty (CPP). […] The main goal of treatment is to help your child grow to a normal adult height. […] How CPP is treated depends on how early it happens and if the cause is known. […] If CPP starts very early, your doctor might want to stop puberty or slow it down. […] So the goal of treatment is to temporarily stop LH and FSH from being released. […] Your doctor may suggest a man-made GnRH medicine to accomplish this. […] Puberty usually will start again about 16 months after your child stops taking the medicine. […] If they discover that a medical issue is the cause of your childs CPP, the doctor will treat that issue.

• #38 2022 Clinical practice guidelines for central precocious puberty of Korean children and adolescents

  https://e-apem.org/journal/view.php?number=994

  Immediate evaluation and treatment are recommended when SCFE, pseudotumor cerebri, or anaphylaxis occurs during GnRH agonist treatment. […] It is recommended to evaluate the effects of GnRH agonist treatment every 3 to 6 months. […] After GnRH agonist treatment, regular follow-up is recommended until the FAH is reached and the recovery of gonadal function is confirmed. […] GnRH agonist treatment does not affect reproductive function nor increase the risk of PCOS in patients with CPP. […] GnRH agonist treatment does not affect metabolic disease, bone health, or mental health in patients with CPP. […] The second edition of 2022 CPGs for the CPP of Korean children and adolescents has been revised and supplements the previous edition based on the latest domestic and international research.

• #39 Management of precocious puberty

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3891356/

  The objectives of treatment for children with central precocious puberty (CPP) are to avoid psychosocial problems caused by early pubertal development and to normalize adult height (AH). A long-acting GnRH analog is the treatment of choice for CPP. GnRH analog administration effectively arrests further development of secondary sex characteristics, slows bone age (BA) maturation, increases pubertal height gain, and is believed to eventually improve AH prognosis. However, the improvement of AH is not well established. It is reported that GnRH analog is effective to improve adult height only in early onset (girls 6 years) CPP. […] The decision to stop therapy should be individualized and based on various factors such as growth velocity, bone age, chronological age, predicted adult height, emotional maturity, and patients wish. […] After treatment discontinuation, long-term follow up is recommended for adult height, reproductive function and bone mineral density.

• #40 A narrative review: treatment outcomes of central precocious puberty (CPP) – Ergun-Longmire – Pediatric Medicine

  https://pm.amegroups.org/article/view/6779/html

  GnRHa remains the preferred treatment in patients with CPP. This treatment is generally considered safe, well-tolerated, and has demonstrated great effectiveness in restoring growth in children with CPP. […] Although more research is needed, the data to date are reassuring that GnRHa treatment in CPP patients does not increase the risk for menstrual or reproductive problems, PCOS, obesity, and bone health.

• #41 2022 Clinical practice guidelines for central precocious puberty of Korean children and adolescents

  https://e-apem.org/journal/view.php?number=994

  Immediate evaluation and treatment are recommended when SCFE, pseudotumor cerebri, or anaphylaxis occurs during GnRH agonist treatment. […] It is recommended to evaluate the effects of GnRH agonist treatment every 3 to 6 months. […] After GnRH agonist treatment, regular follow-up is recommended until the FAH is reached and the recovery of gonadal function is confirmed. […] GnRH agonist treatment does not affect reproductive function nor increase the risk of PCOS in patients with CPP. […] GnRH agonist treatment does not affect metabolic disease, bone health, or mental health in patients with CPP. […] The second edition of 2022 CPGs for the CPP of Korean children and adolescents has been revised and supplements the previous edition based on the latest domestic and international research.

• #42 Treatment of Central Precocious Puberty

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6486823/

  The most commonly reported adverse events are injection-site reactions which are typically mild and self-limited. […] The main goal of treatment in children with CPP is the preservation of height potential. […] A period of observation of 6 months has been recommended unless puberty is quite advanced (Tanner stage 3 breast development in girls) at initial presentation. […] The challenge lies in identifying which patients will ultimately belong in this category as compared with those who will lose a substantial degree of height potential without treatment. […] There are essentially no studies in which age at treatment cessation has been standardized. […] However, cumulative evidence suggests that optimal height gains are realized when treatment is stopped at a bone age of 12 years in girls and 13 years in boys.

• #43 FDA Approves Precocious Puberty Treatment | Consultant360

  https://www.consultant360.com/exclusives/fda-approves-precocious-puberty-treatment

  The FDA has approved Triptodur, Triptorelin 6-month Formulation, for the treatment of pediatric patients 2 years and older with central precocious puberty (CPP). […] The gonadotropin-releasing hormone (GnRH) agonist is administered via intramuscular injection and is the first GnRH agonist to offer once-every-6-months dosing approved for the treatment of CPP in the US. […] The effectiveness of Triptodur was established in a phase III clinical trial in which 93% of participants given the drug experienced a return to pre-pubertal luteinizing hormone levels and pre-pubertal luteinizing hormone suppression maintained at 12 months in 98% of participants. […] The most common adverse events experienced by patients taking Triptodur were injection site reactions and menstrual bleeding.

• #44 Understanding Central Precocious Puberty | LUPRON DEPOT-PED® (leuprolide acetate for depot suspension)

  https://www.lupronped.com/understanding-central-precocious-puberty

  During the first 2 to 4 weeks of treatment, LUPRON DEPOT-PED can cause an increase in some hormones. During this time, you may notice more signs of puberty in your child, including vaginal bleeding. Call your child’s doctor if these signs continue after the second month of treatment with LUPRON DEPOT-PED. […] Your child’s doctor should do tests to make sure your child has CPP before treating them with LUPRON DEPOT-PED. […] LUPRON DEPOT-PED may cause serious side effects. See What is the most important information I should know about LUPRON DEPOT-PED?

• #45 Precocious Puberty Treatment & Management: Approach Considerations, Surgical Care, Medical Care

  https://emedicine.medscape.com/article/924002-treatment

  A literature review by Wang et al found that the addition of growth hormone to GnRH agonist therapy resulted in significant height increase, as well as increases in predicted adult height and height standard deviation for bone age, in children with CPP. Efficacy was greater in patients whose initial treatment began prior to age 10 years or whose therapy lasted more than 12 months. However, the high cost of combined growth hormone-GnRH agonist therapy relative to its modest benefit has generally limited its use to children with a very poor adult height prediction. […] In many cases, the physician may elect to observe the child with CPP, either because the age of onset is borderline (ie, 7-8 y) and the child and family are coping well, or because the progression of puberty is not rapid and the bone age is only mildly advanced, so that predicted adult height falls well within the broad normal range. In these cases, thoughtful counseling of parents about the manageable risks of withholding treatment and follow-up at 6-month intervals are appropriate. Testing and treatment may be initiated if the tempo of puberty begins to accelerate and predicted adult height deteriorates.

• #46 Precocious Puberty Treatment & Management: Approach Considerations, Surgical Care, Medical Care

  https://emedicine.medscape.com/article/924002-treatment

  A literature review by Wang et al found that the addition of growth hormone to GnRH agonist therapy resulted in significant height increase, as well as increases in predicted adult height and height standard deviation for bone age, in children with CPP. Efficacy was greater in patients whose initial treatment began prior to age 10 years or whose therapy lasted more than 12 months. However, the high cost of combined growth hormone-GnRH agonist therapy relative to its modest benefit has generally limited its use to children with a very poor adult height prediction. […] In many cases, the physician may elect to observe the child with CPP, either because the age of onset is borderline (ie, 7-8 y) and the child and family are coping well, or because the progression of puberty is not rapid and the bone age is only mildly advanced, so that predicted adult height falls well within the broad normal range. In these cases, thoughtful counseling of parents about the manageable risks of withholding treatment and follow-up at 6-month intervals are appropriate. Testing and treatment may be initiated if the tempo of puberty begins to accelerate and predicted adult height deteriorates.

• #47 Precocious Puberty: Symptoms, Types, Treatment, and More

  https://www.healthline.com/health/precocious-puberty

  Your child may not need treatment if their precocious puberty is mild or is progressing slowly. They also may not need treatment if the condition develops closer to the age of puberty. […] Treatment will depend on the type of precocious puberty affecting your child. […] The goal of CPP treatment is to pause the pituitary glands production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). […] A medication called a GnRH agonist can help block the glands gonadal activity. Its usually given as an injection every one to three months, or as an implant that slowly releases the medication over the course of a year. […] In addition to slowing puberty, this treatment may allow a child to grow taller than they would have without any treatment. […] After 16 months or so, the treatment usually stops and puberty resumes. […] Because PPP usually stems from an underlying cause, such as a tumor, treating the underlying condition (such as removing the tumor) may be enough to stop the early onset of puberty. […] However, medications to stop the premature production of estrogen and testosterone may also be prescribed.

• #48 Precocious Puberty Treatment & Management: Approach Considerations, Surgical Care, Medical Care

  https://emedicine.medscape.com/article/924002-treatment

  A literature review by Wang et al found that the addition of growth hormone to GnRH agonist therapy resulted in significant height increase, as well as increases in predicted adult height and height standard deviation for bone age, in children with CPP. Efficacy was greater in patients whose initial treatment began prior to age 10 years or whose therapy lasted more than 12 months. However, the high cost of combined growth hormone-GnRH agonist therapy relative to its modest benefit has generally limited its use to children with a very poor adult height prediction. […] In many cases, the physician may elect to observe the child with CPP, either because the age of onset is borderline (ie, 7-8 y) and the child and family are coping well, or because the progression of puberty is not rapid and the bone age is only mildly advanced, so that predicted adult height falls well within the broad normal range. In these cases, thoughtful counseling of parents about the manageable risks of withholding treatment and follow-up at 6-month intervals are appropriate. Testing and treatment may be initiated if the tempo of puberty begins to accelerate and predicted adult height deteriorates.

• #49 Precocious Puberty Treatment & Management: Approach Considerations, Surgical Care, Medical Care

  https://emedicine.medscape.com/article/924002-treatment

  A literature review by Wang et al found that the addition of growth hormone to GnRH agonist therapy resulted in significant height increase, as well as increases in predicted adult height and height standard deviation for bone age, in children with CPP. Efficacy was greater in patients whose initial treatment began prior to age 10 years or whose therapy lasted more than 12 months. However, the high cost of combined growth hormone-GnRH agonist therapy relative to its modest benefit has generally limited its use to children with a very poor adult height prediction. […] In many cases, the physician may elect to observe the child with CPP, either because the age of onset is borderline (ie, 7-8 y) and the child and family are coping well, or because the progression of puberty is not rapid and the bone age is only mildly advanced, so that predicted adult height falls well within the broad normal range. In these cases, thoughtful counseling of parents about the manageable risks of withholding treatment and follow-up at 6-month intervals are appropriate. Testing and treatment may be initiated if the tempo of puberty begins to accelerate and predicted adult height deteriorates.

• #50 Precocious Puberty After Childhood Cancer – Together by St. Jude™

  https://together.stjude.org/en-us/treatment-tests-procedures/long-term-effects/endocrine-late-effects/precocious-puberty.html

  Precocious puberty is one endocrine condition caused by childhood cancer treatment. […] Precocious puberty is not only an early form of puberty, it is also a type of puberty that advances very quickly. It may shorten the period of time during which growth is possible. Children with precocious puberty who do not get treated may have a final adult height that is much shorter than normal. […] If a problem is detected, the provider may refer the survivor to an endocrinologist. The provider may prescribe medications to temporarily stop puberty to allow more time for growth. […] It is also important to evaluate and manage the psychological effects of starting puberty too early. Although children with precocious puberty may have a mature physical appearance, their thoughts, emotions, and behaviors are still that of their actual age.

• #51 Atlanta GA Precocious & Delayed Puberty Treatment | Decatur, Brookhaven

  https://intownpediatrics.com/precocious-or-delayed-puberty/

  Both early and delayed puberty can cause significant emotional and social challenges for children. Children with precocious puberty may feel out of place among their peers, while those with delayed puberty may feel self-conscious about their slower development. […] Early and accurate diagnosis allows us to create a tailored treatment plan that addresses the underlying cause of the condition and promotes healthy growth.

• #52 Precocious puberty: MedlinePlus Medical EncyclopediaLock

  https://medlineplus.gov/ency/article/001168.htm

  Depending on the cause, treatment for precocious puberty may include: […] Medicines to stop the release of sexual hormones, to help delay puberty. These medicines are given as a shot (injection). They will be given until the normal age of puberty. […] Surgery to remove a tumor. […] Parents can support their child by explaining the condition and how their provider plans to treat it. Talking to a mental health worker or counselor may also help.

• #53 Precocious puberty Information | Mount Sinai – New York

  https://www.mountsinai.org/health-library/diseases-conditions/precocious-puberty

  Depending on the cause, treatment for precocious puberty may include: […] Medicines to stop the release of sexual hormones, to help delay puberty. These medicines are given as a shot (injection). They will be given until the normal age of puberty. […] Surgery to remove a tumor. […] Children with early sexual development may have psychological and social problems. Children and adolescents want to be the same as their peers. Early sexual development can make them appear different. Parents can support their child by explaining the condition and how their provider plans to treat it. Talking to a mental health worker or counselor may also help.

• #54 Precocious Puberty After Childhood Cancer – Together by St. Jude™

  https://together.stjude.org/en-us/treatment-tests-procedures/long-term-effects/endocrine-late-effects/precocious-puberty.html

  Precocious puberty is one endocrine condition caused by childhood cancer treatment. […] Precocious puberty is not only an early form of puberty, it is also a type of puberty that advances very quickly. It may shorten the period of time during which growth is possible. Children with precocious puberty who do not get treated may have a final adult height that is much shorter than normal. […] If a problem is detected, the provider may refer the survivor to an endocrinologist. The provider may prescribe medications to temporarily stop puberty to allow more time for growth. […] It is also important to evaluate and manage the psychological effects of starting puberty too early. Although children with precocious puberty may have a mature physical appearance, their thoughts, emotions, and behaviors are still that of their actual age.

• #55 Precocious puberty – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/precocious-puberty/diagnosis-treatment/drc-20351817

  The primary goal of treatment is for children to grow to adult height. […] Treatment for precocious puberty depends on the cause. However, when no cause can be found, treatment may not be needed, depending on the child’s age and how fast puberty is moving. Watching the child for several months might be an option. […] This usually involves medicine called GnRH analogue therapy, which delays further development. It may be a monthly shot with medicine such as leuprolide acetate (Lupron Depot), or triptorelin (Trelstar, Triptodur Kit). Or some newer formulations can be given at longer intervals. […] Children keep getting this medicine until they reach the usual age of puberty. After the treatment stops, puberty starts again. […] Another treatment option for central precocious puberty is a histrelin implant, which lasts up to a year. This treatment doesn’t involve monthly shots. But it does involve minor surgery to put the implant under the skin of the upper arm. After a year, the implant is removed. If needed, a new implant takes its place. […] If another medical condition is causing precocious puberty, stopping puberty means treating that condition. For example, if a tumor makes hormones that cause precocious puberty, puberty usually stops after taking out the tumor.

• #56 Precocious Early Puberty | Boston Children’s Hospital

  https://www.childrenshospital.org/conditions/precocious-early-puberty

  When a child enters puberty (the process of becoming sexual mature) too early, it’s called precocious puberty, or early puberty. […] The goal of treatment for precocious puberty is to stop, and possibly reverse, the onset of puberty. At Children’s, we often use synthetic luteinizing-hormone-releasing hormone (LHRH). […] The goal of treatment for precocious puberty is to stop, and possibly reverse, the onset of puberty. Treatment will also depend on the type of precocious puberty your child has and the underlying cause, if known. […] New developments in treatments for precocious puberty have led to the successful use of synthetic luteinizing-releasing hormone (LHRH). This hormone appears to stop sexual maturation brought on by the disorder by stopping the pituitary gland from releasing gonadotropin. […] Treatment for peripheral precocious puberty depends on what’s causing excess estrogen or androgen production. Options include tumor removal, blocking the actions of estrogen or androgen on the body, or treatment of hypothyroidism with replacement thyroid hormone.

• #57 Treatment of Central Precocious Puberty

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6486823/

  Long-acting analogs of GnRH (GnRHas) have been the gold-standard treatment of central precocious puberty (CPP) worldwide and have an enviable track record of safety and efficacy. […] Safe and effective treatment of CPP in the form of long-acting GnRH analogs (GnRHas) has been available for many years. […] Historically, the most commonly used preparation in the United States for the treatment of CPP was monthly IM depot leuprolide. […] However, during the past decade or so, there has been a substantial increase in the number of extended-release formulations of GnRHas, resulting in a broad array of therapeutic options for patients and providers. […] Although these longer-acting formulations are expected to improve compliance, the cost of GnRHas developed for use in children has remained extremely high.

• #58 Precocious Early Puberty | Boston Children’s Hospital

  https://www.childrenshospital.org/conditions/precocious-early-puberty

  When a child enters puberty (the process of becoming sexual mature) too early, it’s called precocious puberty, or early puberty. […] The goal of treatment for precocious puberty is to stop, and possibly reverse, the onset of puberty. At Children’s, we often use synthetic luteinizing-hormone-releasing hormone (LHRH). […] The goal of treatment for precocious puberty is to stop, and possibly reverse, the onset of puberty. Treatment will also depend on the type of precocious puberty your child has and the underlying cause, if known. […] New developments in treatments for precocious puberty have led to the successful use of synthetic luteinizing-releasing hormone (LHRH). This hormone appears to stop sexual maturation brought on by the disorder by stopping the pituitary gland from releasing gonadotropin. […] Treatment for peripheral precocious puberty depends on what’s causing excess estrogen or androgen production. Options include tumor removal, blocking the actions of estrogen or androgen on the body, or treatment of hypothyroidism with replacement thyroid hormone.

• #59 What Primary Care Providers Need to Know About Precocious Puberty – Pediatrics Nationwide

  https://pediatricsnationwide.org/2024/09/27/what-primary-care-providers-need-to-know-about-precocious-puberty/

  The newer ones have been shown to be equally efficacious in managing early puberty and may offer improved convenience for patient families, such as less-frequent visits to the clinic and less-frequent dosing. […] With these new medications, we now have a wide range of suppressive therapeutic options to use. […] If the GnRHa dose is adequately picked, there will be effective puberty suppression, so we don’t often see treatment failure. […] If families choose to treat precocious puberty with suppression, the drugs are very effective. […] Children with earlier treatment have better outcomes, so we definitely do want PCPs to be watchful and refer early if they suspect something.

Zobacz więcej